COVID-19 and the PAH patient: A retrospective chart review

The COVID-19 pandemic has highlighted the need for additional health precautions in medically fragile populations. COVID-19 is a respiratory virus demonstrating increased mortality in individuals with risk factors such as pulmonary and cardiac disease. Pulmonary arterial hypertension, WHO group 1, is a rare condition that leads to cardiopulmonary symptoms. Pulmonary arterial hypertension, WHO group 1 (PAH), leads to constriction of the pulmonary vasculature which increases pressure in the right ventricle, and eventually leads to right heart failure. Additional research is needed to understand the risk PAH patients have with COVID-19 and if they are at a greater risk for disease worsening as evidenced by increased need for medical intervention, hospitalization, or even death. This project explores the relationship between the COVID-19 pandemic and pulmonary arterial hypertension, WHO group 1, patients at a single center. Adult patients diagnosed with PAH prior to March 1, 2019, at the Ascension St. Vincent Pulmonary Hypertension Clinic will be included in the study. A retrospective chart review will index hospitalization events, markers of disease worsening, and mortality in established patients and compare if there is statistical significance between the pre-pandemic period of March 1, 2019, through February 29, 2020, and during the COVID-19 pandemic period of March 1, 2020, through February 28, 2021. This study will increase the information known about the impact of COVID-19 on patients with PAH.

Creator

• Schmit, Ann

Contributeurs

• Fox, Tara

Language

• English

Mot-clé

• PAH
• COVID-19
• pulmonary arterial hypertension

Date created

• 2021

Resource type

• Research Paper

Rights statement

• http://rightsstatements.org/vocab/InC/1.0/